-
Je něco špatně v tomto záznamu ?
Lignans and Neolignans: Plant secondary metabolites as a reservoir of biologically active substances
F. Zálešák, DJD. Bon, J. Pospíšil,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
- MeSH
- lidé MeSH
- lignany chemie farmakologie MeSH
- rostliny metabolismus MeSH
- sekundární metabolismus MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Lignans and neolignans are plant secondary metabolites derived from the oxidative coupling of phenylpropanoids. Biological activity of these phenolic compounds ranges from antioxidant, antitumor (terminaloside P, IC50 = 10 nM), anti-inflammatory, anti-neurodegenerative (schibitubin B, IC50 = 3.2 nM) and antiviral (patentiflorin A, IC50 = 14-23 nM) to antimicrobial. In addition, it was observed that several members of this group, namely enterolactone and its biochemical precursors also known as phytoestrogens, possess important protective properties. Most of these lignans and neolignans are presented in reasonable amounts in one's diet and thus the protection they provide against the colon and breast cancer, to name a few, is even more important to note. Similarly, neuroprotective properties were observed (schisanwilsonin G, IC50 = 3.2 nM) These structural motives also serve as an important starting point in the development of anticancer drugs. Presumably the most famous members of this family, etoposide and teniposide, synthetic derivatives of podophyllotoxin, are used in the clinical treatment of lymphocytic leukemia, certain brain tumors, and lung tumors already for nearly 20 years. This review describes 413 lignans and neolignans which have been isolated between 2016 and mid-2018 being reported in more than 300 peer-reviewed articles. It covers their source, structure elucidation, and bioactivity. Within the review, the structure-based overview of compounds as well as the bioactivity-based overview of compounds are described.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20023801
- 003
- CZ-PrNML
- 005
- 20201214131240.0
- 007
- ta
- 008
- 201125s2019 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.phrs.2019.104284 $2 doi
- 035 __
- $a (PubMed)31136813
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Zálešák, František $u Department of Organic Chemistry, Faculty of Science, Palacky University, tř. 17. listopadu 1192/12, CZ-771 46 Olomouc, Czech Republic. Electronic address: frantisek.zalesak@upol.cz.
- 245 10
- $a Lignans and Neolignans: Plant secondary metabolites as a reservoir of biologically active substances / $c F. Zálešák, DJD. Bon, J. Pospíšil,
- 520 9_
- $a Lignans and neolignans are plant secondary metabolites derived from the oxidative coupling of phenylpropanoids. Biological activity of these phenolic compounds ranges from antioxidant, antitumor (terminaloside P, IC50 = 10 nM), anti-inflammatory, anti-neurodegenerative (schibitubin B, IC50 = 3.2 nM) and antiviral (patentiflorin A, IC50 = 14-23 nM) to antimicrobial. In addition, it was observed that several members of this group, namely enterolactone and its biochemical precursors also known as phytoestrogens, possess important protective properties. Most of these lignans and neolignans are presented in reasonable amounts in one's diet and thus the protection they provide against the colon and breast cancer, to name a few, is even more important to note. Similarly, neuroprotective properties were observed (schisanwilsonin G, IC50 = 3.2 nM) These structural motives also serve as an important starting point in the development of anticancer drugs. Presumably the most famous members of this family, etoposide and teniposide, synthetic derivatives of podophyllotoxin, are used in the clinical treatment of lymphocytic leukemia, certain brain tumors, and lung tumors already for nearly 20 years. This review describes 413 lignans and neolignans which have been isolated between 2016 and mid-2018 being reported in more than 300 peer-reviewed articles. It covers their source, structure elucidation, and bioactivity. Within the review, the structure-based overview of compounds as well as the bioactivity-based overview of compounds are described.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lignany $x chemie $x farmakologie $7 D017705
- 650 _2
- $a rostliny $x metabolismus $7 D010944
- 650 _2
- $a sekundární metabolismus $7 D064210
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Bon, David Jean-Yves Denis $u Department of Organic Chemistry, Faculty of Science, Palacky University, tř. 17. listopadu 1192/12, CZ-771 46 Olomouc, Czech Republic. Electronic address: david.bon@upol.cz.
- 700 1_
- $a Pospíšil, Jiří $u Department of Organic Chemistry, Faculty of Science, Palacky University, tř. 17. listopadu 1192/12, CZ-771 46 Olomouc, Czech Republic; Laboratory of Growth Regulators, The Czech Academy of Sciences, Institute of Experimental Botany & Palacký University, Šlechtitelů 27, CZ-78371 Olomouc, Czech Republic. Electronic address: j.pospisil@upol.cz.
- 773 0_
- $w MED00005744 $t Pharmacological research $x 1096-1186 $g Roč. 146, č. - (2019), s. 104284
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31136813 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201214131239 $b ABA008
- 999 __
- $a ok $b bmc $g 1596120 $s 1114477
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 146 $c - $d 104284 $e 20190525 $i 1096-1186 $m Pharmacological research $n Pharmacol Res $x MED00005744
- LZP __
- $a Pubmed-20201125